scholarly journals Dry Eye Symptoms and Ocular Pain in Veterans with Glaucoma

2019 ◽  
Vol 8 (7) ◽  
pp. 1076 ◽  
Author(s):  
Aubrey R Tirpack ◽  
Elizabeth Vanner ◽  
James M Parrish ◽  
Anat Galor ◽  
Hong-Uyen Hua ◽  
...  

Dry eye and glaucoma are two frequently encountered ocular conditions, which can lead to substantial morbidity and decreased quality of life. Patients on topical glaucoma medications are known to be at greater risk for ocular surface symptoms. Veterans seen in the eye clinics at the Miami Veterans Affairs Hospital from January to July 2016 completed surveys assessing dry eye and ocular pain symptoms, including the five item Dry Eye Questionnaire (DEQ5). A total of 62 patients with glaucoma completed the survey. Of those, 52 were on glaucoma medications at the time of the survey, with the majority requiring more than one medication to control intraocular pressure. The frequency of mild or greater dry eye symptoms (defined as DEQ5 >6) tended to increase with increasing medication burden, and patients on brimonidine were more likely to report a DEQ5 >6. Patients on three or more glaucoma medications were more likely to report symptoms of shooting pain, dryness, and itchiness. Patients using timolol were more likely to report throbbing and pain by light, while those on latanoprost reported stinging. Our data support an association between increasing number of glaucoma medications and worsening of dry eye symptoms. Patient and medication-associated symptoms can be used to tailor individual medication regimens.

2018 ◽  
Vol 39 (2) ◽  
pp. 419-429 ◽  
Author(s):  
Wenwen Xue ◽  
Ming-ming Zhu ◽  
Bi-jun Zhu ◽  
Jian-nan Huang ◽  
Qian Sun ◽  
...  

Cornea ◽  
2000 ◽  
Vol 19 (Supplement 2) ◽  
pp. S127
Author(s):  
R M Sullivan ◽  
J M Cermak ◽  
A S Papas ◽  
M R Dana ◽  
D A Sullivan

2019 ◽  
Vol 4 (1) ◽  
pp. e000360 ◽  
Author(s):  
Elisabeth Messmer ◽  
Colin Chan ◽  
Penny Asbell ◽  
Gary Johnson ◽  
Brigitte Sloesen ◽  
...  

Background/aimsUnderstanding patients’ perspectives of their disease can inform drug development and treatment decisions. In this study, we compared the preferences and needs of patients with moderate and severe dry eye symptoms from four different countries.MethodsA quantitative questionnaire was developed based on the self-explicated conjoint methodology and was administered to 160 patients with moderate or severe dry eye disease (DED) from Australia, Germany, UK and the USA.ResultsPatients with moderate dry eye symptoms ranked ‘treatment satisfaction’ as the most important aspect, whereas ‘symptom bother’ was more relevant for those in the severe group. Both the moderate and severe groups classified treatment effectiveness as the most important treatment attribute. This result was consistent across the four countries, although US patients gave significantly higher scores than patients from other countries (p<0.001). Furthermore, patients from Australia ranked ‘treatment experience’ as significantly more important than the concern of side effects, whereas respondents from Germany exhibited the opposite trend (p<0.05 for both). The health burden of DED is reflected in the average European Quality of Life-5 Dimensions 5-level (EQ-5D) scores of 0.764 and 0.658 for patients with moderate and severe disease, respectively.ConclusionOur results confirm that across the countries in the study, moderate and severe DED has a major impact on patients’ quality of life and daily activities. By providing insight into the patient perspective of DED, our study helps identify outcomes that are important to patients and may guide future drug development and clinical decision-making.


2020 ◽  
Vol 11 (SPL1) ◽  
pp. 1202-1207
Author(s):  
Pavithra S ◽  
Dheepak Sundar M

To assess dry eye symptoms (DES) and quality of sleep in engineering students during the Covid19 pandemic lockdown and also to assess the association between DES and sleep quality. A cross-sectional questionnaire-based study was carried out among 396 engineering students studying in Saveetha engineering college. The study tool used was a semi-structured google form questionnaire designed for assessing digital device usage, symptoms of dry eye disease and sleep pattern. Responses were analyzed using appropriate statistical tests. Overall 64.1% attained a score of more than 10, indicating the presence of DES. 70.2% of the study population used digital screens for more than 13 hours. A statistically significant association was found between increased screen time and presence of DES(p<0.05). 64.9% had a score of >18 indicating reduced sleep quality. About 77.1% of the students with DES had reduced sleep quality, and a significant association (p<0.01) was observed between the two. During the Covid19 pandemic lockdown, there appears to be rising prevalence of DES in student population, one of the reasons being increased screen time. The sleep quality was also found to be reduced, and a significant association was found between DES and sleep quality.


2021 ◽  
Vol 10 (2) ◽  
pp. 250
Author(s):  
Hyeon Jeong Yoon ◽  
Jonghwa Kim ◽  
Jee Myung Yang ◽  
Edward T. Wei ◽  
Seong Jin Kim ◽  
...  

Background: Activation of TRPM8, a cold-sensing receptor located on the cornea and eyelid, has the potential to relieve the neuropathic ocular pain (NOP) in dry eye (DE) by inhibiting other aberrant nociceptive inputs. We aimed to investigate the effect of a topical TRPM8 agonist, cryosim-3 (C3), on relieving DE-associated NOP. Methods: We conducted a prospective pilot study of 15 patients with DE-associated NOP. These patients applied topical C3 to their eyelid, 4 times/day for 1 month. The patients underwent clinical examinations. They also completed the Ocular Pain Assessment Survey (OPAS), which is a validated questionnaire for NOP, at baseline, 1 week, and 1 month after treatment. Result: At 1 week, the OPAS scores of eye pain intensity, quality of life (driving/watching TV, general activity, sleep, and enjoying life/relations with other people), and associated factors (burning sensation, light sensitivity, and tearing) improved. The total OPAS scores of eye pain intensity, quality of life, and associated factors remained improved at 1 month. The Schirmer test scores also improved at 1 month. Conclusion: TRPM8 agonist (C3) could be a novel agent for treating patients with DE-associated NOP who are unresponsive to conventional treatments.


2018 ◽  
Vol 44 ◽  
pp. S307-S313 ◽  
Author(s):  
Victoria S. Chang ◽  
Terri P. Rose ◽  
Carol L. Karp ◽  
Roy C. Levitt ◽  
Constantine Sarantopoulos ◽  
...  

2017 ◽  
Vol 43 (3) ◽  
pp. 192-198 ◽  
Author(s):  
Jerry P. Kalangara ◽  
Anat Galor ◽  
Roy C. Levitt ◽  
Derek B. Covington ◽  
Katherine T. McManus ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document